Recommended
OUR SERVICE
In all critical stages in the drug life cycle, BaiPharm can provide specific recommendations
and actionable solutions to clients.
VIEW MORE >
Consulting of current regulation and policy

NMPA related application for clinical trial and marketing approval

Compliance support from product development to commercialization

Post-market drug safety and risk management

Latest News

REGULATION
Law & Regulation
MAH
Pharmacovigilance
Marketing Approval
Priority Review and Approval
Medical Insurance
Innovative Drug
Generic Drug
Rare Disease
Drug Registration
New Drug
China Encourages Innovative Drug R&D in Revised Draft of Regulations for Implementing the Drug Administration Law
Find out the highlights in revised draft of the Regulations for Implementation of the Drug Administration Law: pharmaceutical innovation, acceptance of foreign clinical data, support the development of pediatric and rare disease drugs...
May 13, 2022

INDUSTRY
MAH
Marketing Approval
Priority Review and Approval
Innovative Drug
Generic Drug
Biological Product
Cancer
Drug Registration
New Drug
Monthly Report: New Drug Approvals in China | April 2022
In April 2022, China NMPA approved 23 new drugs, including 20 chemical drugs and 3 biological products.
May 12, 2022